Servier is an independent international pharmaceutical group operating under a unique governance model governed by a foundation. The company is dedicated to therapeutic progress and emphasizes the integration of the patient voice at every stage of the medicine life cycle.
Known as a prominent global leader in the fields of cardiology and venous diseases, Servier has set its sights on becoming a frontrunner in oncology and neurology as well. By utilizing precision medicine, the group endeavors to deliver targeted therapeutic solutions for rare diseases, underpinning this ambition by allocating nearly 20% of its brand-name sales to R&D.
Headquartered in France, the company employs over 20,000 individuals and boasts a robust international presence with its medicines available in more than 130 countries. In the 2024/25 financial year, Servier reported impressive revenues totaling €6.9 billion.